Skip to main content
. 2023 Oct;131(4):466–473.e6. doi: 10.1016/j.anai.2023.06.024

eTable 5.

Participants With Allergic Comorbidities in Each Wheeze Trajectory

Allergic comorbidities Total (n = 974) No or low wheeze (n = 812) Early-onset transient (n = 44) P Late-onset transient (n = 79) P Persistent (n = 39) P
Allergic sensitization by 1.5 y 115 (13.9) 84 (12.1) 2 (5.3) .30 18 (27.7) <.001 11 (32.4) .002
Allergic sensitization by 3 y 231 (29.6) 169 (26.2) 13 (34.2) .28 31 (47.0) <.001 18 (58.1) <.001
Allergic sensitization by 5 y 351 (47.8) 270 (44.9) 18 (48.7) .66 37 (56.9) .07 26 (83.9) <.001
Allergic sensitization by 8 y 515 (70.0) 411 (68.3) 27 (75.0) .40 45 (72.6) .49 32 (88.9) .009
Eczema by 1.5 y 166 (21.5) 112 (17.6) 12 (32.4) .02 24 (36.4) <.001 18 (52.9) <.001
Eczema by 3 y 209 (28.4) 146 (24.3) 13 (35.1) .14 31 (47.0) <.001 19 (59.4) <.001
Eczema by 5 y 226 (33.5) 158 (28.8) 15 (42.9) .08 32 (51.6) <.001 21 (70.0) <.001
Eczema by 8 y 266 (33.8) 192 (29.6) 17 (46.0) .04 36 (53.7) <.001 21 (61.8) <.001
Rhinitis by 1.5 y 397 (49.7) 300 (45.9) 33 (84.6) <.001 40 (58.8) .04 24 (63.2) .04
Rhinitis by 3 y 489 (61.1) 380 (57.8) 34 (85.0) .001 48 (70.6) .04 27 (77.1) .02
Rhinitis by 5 y 509 (65.9) 399 (62.9) 34 (85.0) .005 49 (75.4) .046 27 (79.4) .051
Rhinitis by 8 y 548 (64.1) 432 (61.3) 35 (81.4) .008 54 (77.1) .009 27 (73.0) .15
Atopic eczema by 1.5 y 40 (5.7) 24 (4.1) 1 (2.9) >.99 6 (10.5) .03 9 (30.0) <.001
Atopic eczema by 3 y 70 (10.4) 40 (7.3) 6 (16.7) .04 11 (18.6) .003 13 (46.4) <.001
Atopic eczema by 5 y 93 (15.8) 56 (11.7) 8 (23.5) .04 15 (28.3) .001 14 (58.3) <.001
Atopic eczema by 8 y 143 (20.0) 101 (17.0) 7 (21.9) .48 17 (29.8) .02 18 (56.3) <.001
Atopic rhinitis by 1.5 y 61 (8.6) 42 (7.1) 2 (5.9) >.99 9 (16.1) .02 8 (23.5) .001
Atopic rhinitis by 3 y 108 (15.2) 71 (12.1) 8 (21.1) .11 18 (31.0) <.001 11 (36.7) <.001
Atopic rhinitis by 5 y 144 (22.2) 100 (18.8) 13 (37.1) .008 18 (34.0) .008 13 (48.2) <.001
Atopic rhinitis by 8 y 236 (32.8) 183 (30.6) 15 (45.5) .07 21 (38.2) .25 17 (51.5) .01
Eczema with steroids use by 1.5 y 92 (12.7) 61 (10.1) 7 (20.0) .07 13 (22.0) .006 11 (36.7) <.001
Eczema with steroids use by 3 y 112 (16.7) 76 (13.7) 7 (20.6) .27 16 (29.1) .002 13 (46.4) <.001
Eczema with steroids use by 5 y 120 (20.2) 82 (16.7) 7 (23.3) .35 18 (36.0) .001 13 (52.0) <.001
Eczema with steroids use by 8 y 161 (21.4) 114 (18.4) 10 (27.8) .16 22 (34.4) .002 15 (45.5) <.001
Sensitization to food by 1.5 y 38 (4.6) 27 (3.9) 1 (2.6) >.99 4 (6.2) .33 6 (17.7) .003
Sensitization to food by 3 y 45 (5.9) 33 (5.2) 2 (5.4) >.99 4 (6.5) .56 6 (20.0) .006
Sensitization to food by 5 y 74 (11.1) 55 (10.0) 4 (11.4) .77 8 (14.8) .27 7 (28.0) .01
Sensitization to food by 8 y 117 (19.6) 80 (16.2) 9 (28.1) .08 15 (31.9) .007 13 (54.2) <.001
Sensitization to dust mite by 1.5 y 95 (11.4) 70 (10.1) 1 (2.6) .16 16 (24.2) .001 8 (23.5) .02
Sensitization to dust mite by 3 y 212 (27.1) 155 (23.9) 12 (31.6) .29 29 (43.9) <.001 16 (53.3) <.001
Sensitization to dust mite by 5 y 334 (45.6) 255 (42.5) 18 (48.7) .46 36 (55.4) .047 25 (83.3) <.001
Sensitization to dust mite by 8 y 502 (68.8) 400 (66.9) 27 (75.0) .31 43 (71.7) .45 32 (88.9) .006

NOTE. Sample used to study the associations was smaller because of missing values. Benjamini-Hochberg procedure with a 5% false discovery rate was applied.